WALTHAM, Mass. - Dragonfly Therapeutics, Inc., a biotechnology firm specializing in immunotherapy treatments, has announced the initiation of a clinical trial by AbbVie (NYSE: NYSE:ABBV) for ABBV-303, an investigational drug designed to combat solid tumors.
The trial marks the first patient dosing, a milestone that has triggered a payment to Dragonfly under the terms of their collaboration.
ABBV-303 is the latest offering from Dragonfly's technology platform and the first TriNKET® drug from their partnership with AbbVie to be tested in a clinical setting. The Phase 1 trial is designed to assess the safety and efficacy of ABBV-303, both as a standalone therapy and in combination with another AbbVie drug, budigalimab (ABBV-181), which also targets solid tumors.
Bill Haney, CEO and co-founder of Dragonfly, expressed enthusiasm about the partnership with AbbVie, citing the company's reputation for pioneering treatments for complex diseases. Haney anticipates continued progress with AbbVie in developing new treatment options for patients.
The trial, identified as M24-122 Phase 1, is part of a broader effort by Dragonfly to leverage its proprietary platforms to create a pipeline of preclinical candidates and collaborate with industry leaders like Merck, Gilead (NASDAQ:GILD), and Bristol Myers (NYSE:BMY) Squibb.
As the trial progresses, further updates and details can be accessed through the clinical trials registry website. This clinical advancement represents a significant step in Dragonfly's mission to harness the immune system for the development of innovative treatments.
The information presented in this article is based on a press release statement from Dragonfly Therapeutics, Inc.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.